Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.14EUR
259.75 MEUR
946.46 MEUR
123.13 M
About HANGZHOU TIGERMED
Sector
CEO
Xiao Chun Cao
Website
Headquarters
Hangzhou
Founded
2004
ISIN
CNE1000040M1
FIGI
BBG011FHLGR4
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange HANGZHOU TIGERMED CO. H 1 stocks are traded under the ticker 5HZ1.
We've gathered analysts' opinions on HANGZHOU TIGERMED CO. H 1 future price: according to them, 5HZ1 price has a max estimate of 11.08 EUR and a min estimate of 3.38 EUR. Watch 5HZ1 chart and read a more detailed HANGZHOU TIGERMED CO. H 1 stock forecast: see what analysts think of HANGZHOU TIGERMED CO. H 1 and suggest that you do with its stocks.
5HZ1 reached its all-time high on Jul 2, 2021 with the price of 18.98 EUR, and its all-time low was 0.001 EUR and was reached on Mar 13, 2008. View more price dynamics on 5HZ1 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track HANGZHOU TIGERMED CO. H 1 financials in yearly and quarterly reports right on TradingView.
HANGZHOU TIGERMED CO. H 1 is going to release the next earnings report on Mar 31, 2025. Keep track of upcoming events with our Earnings Calendar.
5HZ1 earnings for the last quarter are 0.05 EUR per share, whereas the estimation was 0.07 EUR resulting in a −31.55% surprise. The estimated earnings for the next quarter are 0.07 EUR per share. See more details about HANGZHOU TIGERMED CO. H 1 earnings.
HANGZHOU TIGERMED CO. H 1 revenue for the last quarter amounts to 215.48 M EUR, despite the estimated figure of 256.51 M EUR. In the next quarter, revenue is expected to reach 269.28 M EUR.
5HZ1 net income for the last quarter is 40.29 M EUR, while the quarter before that showed 33.26 M EUR of net income which accounts for 21.15% change. Track more HANGZHOU TIGERMED CO. H 1 financial stats to get the full picture.
Yes, 5HZ1 dividends are paid annually. The last dividend per share was 0.07 EUR. As of today, Dividend Yield (TTM)% is 1.77%. Tracking HANGZHOU TIGERMED CO. H 1 dividends might help you take more informed decisions.
HANGZHOU TIGERMED CO. H 1 dividend yield was 1.76% in 2023, and payout ratio reached 24.09%. The year before the numbers were 0.68% and 22.70% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 31, 2024, the company has 9.70 K employees. See our rating of the largest employees — is HANGZHOU TIGERMED CO. H 1 on this list?
Like other stocks, 5HZ1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANGZHOU TIGERMED CO. H 1 stock right from TradingView charts — choose your broker and connect to your account.